Assessment of Retreatment With Lutathera in Patients With New Progression of Intestinal Well-differenciated NET

In France, since the reimbursement of Lutathera, this treatment is allowed for retreatment if patients still fulfill the criteria of its indication and 4 news cycles could be proposed. However, clinical practices are heterogeneous regarding the number of new cycles and most teams perform only two additional cycles (every 8 weeks). Therefore, the coordinator propose to evaluate the efficacy of two additional cycle of Lutathera versus active surveillance in patients already retreated with two cycles Lutathera for a new progression of intestinal neuroendocrine tumor and who previously received the 4 cycles of treatment with a clinical benefit.